WallStreetZenWallStreetZen

NYSEMKT: AEON
Aeon Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their AEON stock forecasts and price targets.

Forecast return on equity

Is AEON forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is AEON forecast to generate an efficient return on assets?

Company
N/A
Industry
31.3%

AEON earnings per share forecast

What is AEON's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.71
Avg 2 year Forecast
-$0.43

AEON revenue forecast

What is AEON's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$2.4M
Avg 3 year Forecast
$36.7M

AEON vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AEON$1.07N/AN/A
NEUP$5.03$7.00+39.17%Buy
NNVC$1.28N/AN/A
AIXC$1.37N/AN/A
TPST$1.94$11.00+467.01%Buy
View Top Biotech Stocks

Aeon Biopharma Stock Forecast FAQ

What is AEON's earnings growth forecast for 2026-2027?

(NYSEMKT: AEON) Aeon Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.67%.

Aeon Biopharma's earnings in 2026 is -$39,222,000.On average, 3 Wall Street analysts forecast AEON's earnings for 2026 to be -$18,066,383, with the lowest AEON earnings forecast at -$17,357,898, and the highest AEON earnings forecast at -$18,597,748.

In 2027, AEON is forecast to generate -$10,839,830 in earnings, with the lowest earnings forecast at -$10,414,739 and the highest earnings forecast at -$11,158,649.

If you're new to stock investing, here's how to buy Aeon Biopharma stock.

What is AEON's revenue growth forecast for 2026-2028?

(NYSEMKT: AEON) Aeon Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.37%.

Aeon Biopharma's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast AEON's revenue for 2026 to be $0, with the lowest AEON revenue forecast at $0, and the highest AEON revenue forecast at $0. On average, 3 Wall Street analysts forecast AEON's revenue for 2027 to be $60,904,461, with the lowest AEON revenue forecast at $58,525,973, and the highest AEON revenue forecast at $62,700,978.

In 2028, AEON is forecast to generate $929,128,290 in revenue, with the lowest revenue forecast at $892,691,886 and the highest revenue forecast at $956,455,592.

What is AEON's forecast return on assets (ROA) for 2026-2029?

(NYSEMKT: AEON) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 31.3%.

What is AEON's Earnings Per Share (EPS) forecast for 2026-2027?

(NYSEMKT: AEON) Aeon Biopharma's current Earnings Per Share (EPS) is -$3.95. On average, analysts forecast that AEON's EPS will be -$0.71 for 2026, with the lowest EPS forecast at -$0.69, and the highest EPS forecast at -$0.74. In 2027, AEON's EPS is forecast to hit -$0.43 (min: -$0.41, max: -$0.44).

What is AEON's forecast return on equity (ROE) for 2026-2029?

(NYSEMKT: AEON) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.